Combination therapies are getting increased attention to overcome unresponsiveness to ICB and using Poly (I:C) with anti-PD-L1 demonstrated improved efficacy compared to the single agents alone, in three cancer mouse models (melanoma, lung, and colon) [238]. This evidence concerns the gene CD274 and cancer.